Endocyte Added to NASDAQ Biotechnology Index
December 15 2017 - 8:00AM
Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that it has been selected for addition to the
NASDAQ Biotechnology Index® (NASDAQ:NBI). Endocyte’s addition to
the NBI will become effective prior to market open on Monday, Dec,
18, 2017.
The NASDAQ Biotechnology Index (NBI) contains securities of
NASDAQ-listed companies that meet certain eligibility criteria, and
are classified according to the Industry Classification Benchmark
as either Biotechnology or Pharmaceuticals. These requirements
include minimum market capitalization, and average daily trading
volume. For more information about the NASDAQ Biotechnology Index
visit https://indexes.nasdaqomx.com.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company’s drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte’s lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering Phase 3 for metastatic castration resistant prostate
cancer (mCRPC). Endocyte is also advancing its adaptor-controlled
CAR-T therapy into the clinic in 2018, where it will be studied in
pediatric osteosarcoma. For additional information, please visit
Endocyte's website at www.endocyte.com.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to future spending,
future cash balances, the timing of initiation and completion of
clinical trials, estimates of the potential market
opportunity for the company’s product candidates, and the company's
future development plans including those relating to the completion
of pre-clinical development in preparation for possible future
clinical trials. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include risks
that the company or independent investigators may experience delays
in the initiation of completion of clinical trials (whether caused
by competition, adverse events, patient enrollment rates, shortage
of clinical trial materials, regulatory issues or other factors);
risks that data from prior clinical trials may not be indicative of
subsequent clinical trial results; risks related to the safety and
efficacy of the company’s product candidates; risks that early
stage pre-clinical data may not be indicative of subsequent data
when expanded to additional pre-clinical models or to subsequent
clinical data; risks that evolving competitive activity and
intellectual property landscape may impair the company's ability to
capture value for the technology; risks that expectations and
estimates turn out to be incorrect, including estimates of the
potential markets for the company’s product candidates, estimates
of the capacity of manufacturing and other facilities required to
support its product candidates, projected cash needs, and expected
future revenues, operations, expenditures and cash position. More
information about the risks and uncertainties faced by Endocyte,
Inc. is contained in the company’s periodic reports filed with the
Securities and Exchange Commission. Endocyte, Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212)
362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2023 to Apr 2024